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The recent changes in the guidance issued by the National Institute for Health 
and Care Excellence (NICE) regarding the use of endovascular aneurysm 
repair highlight many of the difficulties faced in the evaluation and introduction 
of new interventional procedures.  This paper questions whether the current 
processes for evaluation, largely based upon cost-utility analysis, are 
adequate to address the issues raised by such technologies.  In particular, it 
considers the implications of rapidly evolving technologies, time preferences 
and process utilities for the evaluation and introduction of new procedures and 
devices.    
Introduction 
Guidance issued by the National Institute for Health and Care Excellence 
(NICE) regarding the use of endovascular aneurysm repair (EVAR) for 
abdominal aortic aneurysm (AAA) illustrates many of the difficulties inherent in 
providing evidence-based advice to the NHS.   
The procedures and devices used for EVAR have developed rapidly over the 
past 20 years and many now consider it the first line elective treatment for AAA 
in most circumstances.  The procedure has been considered by NICE on 
several occasions through different processes (see Table 1).  Following 
publication of the early results of the EVAR trials 1, it was considered sufficiently 
safe and efficacious for use in the NHS (IPG163).  The 2009 appraisal (TA167) 
recommended it as a treatment option for patients with unruptured infra-renal 
abdominal aortic aneurysms with some anatomical, clinical and demographic 
factors to be taken into account in making the decision.  The guidance appeared 
to partly contradict the findings of the assessment report, which demonstrated 
that EVAR was unlikely to be cost effective in fit patients, when compared to 
open surgical repair. 2 
EVAR has been widely adopted in the NHS, now accounting for about 70% of 
elective cases 3 and is used increasingly in emergency cases, following 
promising trial results. 4  The concurrent introduction of aneurysm screening 
has increased the proportion of younger and fitter patients undergoing elective 
aneurysm repair, the group least likely to be cost effective, according to the 
economic modelling. 2 
The draft NICE guidance issued in May 2018, suggesting EVAR should not be 
offered to people with an unruptured infrarenal AAA, has proved controversial, 
and a joint statement from several professional societies has condemned the 
guidance 5.   
NICE decision-making 
IPAC considers only safety and efficacy, whilst technology appraisal and 
guidelines include detailed assessment of cost effectiveness.  However, NICE 
states that it does not prescribe to a specifically utilitarian approach, but 
focusses on ‘procedural justice’ that has amongst its principles; scientific rigour, 
inclusiveness, transparency and independence. 6 
NICE methods guidance describes, in considerable detail, the methods of 
technology appraisal, including the cost effectiveness analysis to be 
undertaken, 7 specifying the perspective of the health and social care system, 
and a version of cost effectiveness based upon the cost per quality adjusted 
life year (QALY).  QALYs are based upon their preferred health outcome 
measure, the EQ-5D, a generic measure with five dimensions, each valued on 
a three-point scale and converted to a utility using a standard tariff.  A 
‘discounted cost-per-QALY’ is compared to a nominal ‘willingness-to-pay’ 
threshold of £20,000 per QALY, which, in certain circumstances, can be 
extended to £30,000. 
The threshold was set nearly 20 years ago and some empirical evidence 
suggests that this may already be set too high, 8 whilst many technologies are 
approved well above this threshold, 9 and subsequent changes have stretched 
this further for end-of-life drugs 10 and highly specialised technologies. 11 
Apart from concerns about aspects of health outcomes that are not adequately 
captured by EQ-5D 12, other aspects of healthcare provision that are valued by 
society, are excluded from the calculations.  These include issues such as 
equity, burden of disease, wider societal impacts, autonomy, dignity, continuity 
of care, location of services and aspects of the process of care, such as the 
invasiveness of treatment.   NICE considered including some of these issues 
in relation to ‘value-based pricing’ in 2014, but dropped the proposals following 
consultation. 13 14 
Issues for interventional procedures 
Although there is no ‘gold-standard’ for methods of evaluation, the choice may 
have significant impact on the technologies that appear advantaged or 
disadvantaged.  Specific considerations are of particular relevance to 
interventional procedures. 
Process utilities  
The ‘process utility’ is the additional value that might be attached to particular 
modes of treatment, such as different routes of administration, outpatient vs. 
inpatient treatment or more or less invasive methods.  Evidence suggests that 
these may be valued over and above any short-lived differences in health 
captured by instruments such as the EQ-5D. 15 
NICE may consider such preferences through its deliberative processes, for 
example, using a raised threshold to allow for the convenience of the oral rather 
that parenteral administration.  However, major surgical procedures, compared 
to minimally invasive or medical options, are of a different order of magnitude 
and adjusting the threshold to allow for this may be unsatisfactory (see below). 
Time preferences 
Major surgical procedures may result in very different risk profiles compared to 
less invasive or conservative treatments.  To someone needing treatment in 
their 80’s for AAA, the risk of procedure-related mortality for open repair may 
be 5-10% with EVAR carrying about one-third of this risk. 16  This early 
advantage may be given far more weight than risks of complications and 
retreatments years in the future.  The strength of this preference is unlikely to 
be adequately represented by the discount rate of 3.5%, used for NICE 
economic evaluations. 17 
Evolving technologies 
Drugs are stable technologies with pivotal clinical studies prior to licensing, 
defining the formulation and dosage regimes.  In contrast, interventional 
technologies are usually evolving, creating difficulties in assessing and applying 
evidence of effectiveness to procedures that are in a state of flux, or devices 
that may no longer be current.   
A changing selection of EVAR devices and techniques may suit patients with 
specific clinical and anatomical characteristics.  Thus, unlike drugs for which 
indications and are clearly defined, clinicians are not simply learning a new 
procedure, but developing experience in how particular methods or devices will 
suit individual circumstances. 
Pricing and costs 
Drug prices are fixed through various national mechanisms and there is an 
opportunity for (indirect) negotiation through patient access schemes. 18 There 
are no such fixed prices or opportunity for national negotiation for devices and 
a significant aspect of the cost of procedures may relate to hospital and staffing 
resources, which vary between centres, may be affected by individual patient 
characteristics and are subject to differences in practice. 
Wider impacts 
Choices between different modalities of treatment will often have implications 
for wider aspects of service configuration, such as the location of services, 
training requirements, the need for capital equipment, shifts in workload or joint 
working between specialities.  Such changes may result in significant sunk cost 
or organisational changes associated with the new technology. 
The evaluation of EVAR 
Modelling of cost effectiveness using the methodology and limits usually set by 
NICE has been consistent in finding that, for relatively young and fit patients, 
EVAR is unlikely to be cost effective, and may be dominated by open repair.  
Most models have considered alternative scenarios and subgroup analyses, 
and suggest that there are older, less fit people, for whom EVAR is a cost-
effective option. 2 19 Modelling for the guideline did not consider such alternative 
scenarios in detail and identifying an appropriate subgroup is not easy, due to 
the absence of accepted methods for risk scoring, lack of relevant anatomical 
and clinical data, and reluctance to use factors such as age and gender to 
determine treatment policies. 
The appraisal in 2009, despite evidence that the procedure was unlikely to be 
cost effective on average, 2 allowed clinical discretion, but drew attention to 
factors that may be relevant to the decision.  This appeared, in effect, to place 
responsibility for cost effective decision-making on the individual clinician.  This 
proved unsatisfactory for several reasons.   
Whilst those with clinical expertise are clearly important stakeholders in 
determining guidelines under which new technologies are made available, it is 
important to separate their policy role from their dealings with individual 
patients.  Patients expect that individual clinical advice is based upon the most 
effective treatment available and to base such advice on budgetary 
considerations is likely to undermine the relationship of trust between clinician 
and patient.   Experience also tells us that such discretion is likely to favour 
more informed and empowered groups within society. 20 In the case of EVAR it 
is clear that asking clinicians to make decisions based upon cost effectiveness 
was ineffective.  Given clinical freedom, decisions reflect the personal 
preferences of the clinician and/or patient. 
Improving decision-making 
There is no ‘right’ or ‘wrong’ method for making decisions about the distribution 
of scarce healthcare resources.  With many competing demands on resources, 
trade-offs are required between utilitarian approaches that might maximise 
differing measures of benefit, and other libertarian or egalitarian considerations.  
However, in a publicly funded healthcare system in a democratic society it is, 
perhaps, reasonable to expect that the process results in decisions that broadly 
reflect societal preferences.  There are a number of measures relating to NICE 
methods, or areas where further research is required, that might help achieve 
this aim. 
Better measures of health utility 
The primary outcome measure recommended by NICE for generating the 
utilities used in calculating QALYs is the tariff derived from the EQ-5D.  This 
lacks sensitivity to small changes in health status and does not address 
significant aspects of health that may be considered important. 12 This has 
resulted in the development of a five-level version of the measure and the 
suggestion of various ‘bolt-ons’ to address areas such as hearing and visual 
impairment. 21  NICE has not currently adopted these modifications.   
Valuing process utility 
In addition to the health outcomes measured by EQ-5D, processes of care may 
be very important to patients, particularly in relation to interventional procedures 
where options may include major invasive surgery.  It is possible to measure 
the value that is put on aspects of process, and formally consider trade-offs 
against other aspects of outcome. 22 
Wider aspects 
Healthcare decisions are not made in isolation, and healthcare and health 
outcomes have wider societal and personal impacts.  Whilst NICE considered 
some of these issues as part of the consultation on value-based-pricing, they 
decided against formally including them in calculations of cost effectiveness. 13 
Considering net benefit 
The use of a cost effectiveness threshold, which is varied in certain 
circumstances, has resulted in a system which tends to favour certain 
technologies, particularly end-of-life drugs and highly specialised technologies.  
The deliberative process used for NICE decision-making, accounts for ‘other 
factors’ by raising (never lowering) the threshold in certain circumstances.  
Additional factors are only considered in relation to the new technology under 
consideration and not in relation to any existing technology that is likely to be 
displaced.  Disinvestment decisions do not undergo the same level of scrutiny 
as new technologies and are often invisible to decision-makers and service 
users who may be affected by such decisions.  To include consideration of more 
sensitive or inclusive outcome measures, process utilities or wider impact, 
requires that such criteria are extended to potentially displaced activities. 
Accounting for such factors by adjusting the threshold particularly benefits high-
cost interventions.  An alternative approach would be to calculate net monetary 
or health benefit (or cost).  A committee might consider it worth a few additional 
pounds per patient for a less invasive procedure, but not several thousand 
pounds, a difference that may not be apparent when considering this in terms 
of ICERs and thresholds (see Table 2). 
Admitting to uncertainty 
NICE guidance is based upon evidence that is subject to considerable 
uncertainty, but clear guidance may inhibit further research. Evidence regarding 
EVAR has changed little since the original randomised trials and it is unlikely 
that further randomised studies would be feasible.  Data collected through the 
National Vascular Registry lacks long-term follow up, 3 whilst routine data can 
reveal readmissions, re-treatment and mortality, but does not include detailed 
clinical or anatomical information.   
If the modelled costs are accurate then it is likely that EVAR has cost the NHS 
in excess of an additional £100 million since the appraisal in 2009.  A decision 
at that time for ‘coverage with evidence’ could, at a small fraction of this cost, 
have provided the evidence for detailed predictive models, which could be used 
to identify appropriate populations for the cost-effective use of EVAR.  
Unfortunately, the financial arrangements that separate clinical and research 
budgets may mitigate against decisions that are subject to further research and 
evidence collection. 
Conclusions 
Whilst the problems encountered in providing guidance about EVAR are not 
unique, there are various issues that are specific to, or more significant, when 
considering interventional procedures.  Since all NICE decisions are ultimately 
based upon societal preferences, it seems inconsistent to consider only the 
preferences for the narrow range of dimensions incorporated in the EQ-5D, and 
not for care processes or wider impacts that may be valued by society.   
Whilst further research is needed to evaluate the strength of such preferences, 
a move towards the use of net benefits, rather than a variable ICER threshold, 
may provide more transparency regarding the weight that is given to such 
considerations.  However, the inclusion of other criteria is complicated by the 
need to ensure that any such modifications in process are applied equally to 
technologies that may be displaced, rather than simply inflating the price that 
the NHS is willing to pay for new technologies.  
With technologies that are new and evolving, or where evidence is immature, a 
more flexible approach to approval for use with evidence collection, or ‘only in 
research’ may help to avoid the threatened reversals that have occurred in the 
evaluation of EVAR. 
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